CEL-SCI Corp (CVM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
72
About the Report
About the Report
Summary
CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI's lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.
CEL-SCI Corp (CVM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
CEL-SCI Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
Equity Offering 15
CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15
CEL-SCI Raises USD5 Million in Private Placement of Shares 16
CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17
CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18
CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19
CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28
CEL-SCI Raises USD5 Million in Registered Direct Offering 29
CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30
CEL-SCI Raises USD1.1 Million in Private placement of Shares 31
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36
Cel-Sci Raises USD3 Million upon Exercise of Warrants 38
Cel-Sci Completes Public Offering Of Units For USD 10 Million 39
Cel-Sci Completes Public Offering Of Units For USD 3.3 Million 40
Cel-Sci Completes Public Offering Of Units For USD 17.8 Million 42
Cel-Sci Completes Public Offering Of Common Stock For USD 11 Million 44
Cel-Sci Files Registration Statement For Public Offering Of Securities For USD 50 Million 45
Cel-Sci Completes Private Placement Of Common Stock For USD 6 Million 46
CEL-SCI Completes Private Placement Of Common Stock For USD 5.8 Million 47
Debt Offering 48
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49
CEL-SCI Corp-Key Competitors 50
CEL-SCI Corp-Key Employees 51
CEL-SCI Corp-Locations And Subsidiaries 52
Head Office 52
Recent Developments 53
Financial Announcements 53
Aug 14, 2018: CEL-SCI reports third quarter fiscal year 2018 financial results 53
May 15, 2018: CEL-SCI Announces Second Quarter Fiscal 2018 Financial Results 54
Feb 12, 2018: CEL-SCI Reports First Quarter Fiscal 2018 Financial Results 55
Dec 29, 2017: CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments 56
Aug 09, 2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results 57
May 10, 2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results 58
Feb 09, 2017: CEL-SCI Reports First Quarter Fiscal 2017 Financial Results 59
Corporate Communications 60
Aug 17, 2018: CEL-SCI Announces that the NYSE American approves plan 60
Dec 18, 2017: CEL-SCI Announces Robert Watson Joins its Board of Directors 61
Feb 27, 2017: CEL-SCI Announces That the NYSE MKT Approves Plan 62
Government and Public Interest 63
Sep 19, 2017: CEL-SCI Announces USD 1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine 63
Product News 64
05/16/2017: CEL-SCI Scientist Presents Data on CEL-4000 at AAI-IMMUNOLOGY 2017 Meeting 64
04/12/2017: CEL-SCI Scientist Presents at the World Vaccine Congress 65
02/21/2017: CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference 66
Clinical Trials 67
Jun 08, 2017: CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal 67
Other Significant Developments 68
Jun 11, 2018: CEL-SCI Issues Letter to Shareholders 68
Apr 04, 2018: CEL-SCI: Letter to Shareholders 69
Jan 03, 2018: CEL-SCI Releases Letter to Shareholders 70
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
List of Figure
List of Figures
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
CEL-SCI Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CEL-SCI Corp, Deals By Therapy Area, 2012 to YTD 2018 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15
CEL-SCI Raises USD5 Million in Private Placement of Shares 16
CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17
CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18
CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19
CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28
CEL-SCI Raises USD5 Million in Registered Direct Offering 29
CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30
CEL-SCI Raises USD1.1 Million in Private placement of Shares 31
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36
Cel-Sci Raises USD3 Million upon Exercise of Warrants 38
Cel-Sci Completes Public Offering Of Units For USD 10 Million 39
Cel-Sci Completes Public Offering Of Units For USD 3.3 Million 40
Cel-Sci Completes Public Offering Of Units For USD 17.8 Million 42
Cel-Sci Completes Public Offering Of Common Stock For USD 11 Million 44
Cel-Sci Files Registration Statement For Public Offering Of Securities For USD 50 Million 45
Cel-Sci Completes Private Placement Of Common Stock For USD 6 Million 46
CEL-SCI Completes Private Placement Of Common Stock For USD 5.8 Million 47
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49
CEL-SCI Corp, Key Competitors 50
CEL-SCI Corp, Key Employees 51
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.